UroGen Pharma Ltd URGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $40.23
- Day Range
- $38.28–40.35
- 52-Week Range
- $13.79–40.35
- Bid/Ask
- $37.80 / $39.01
- Shares Outstanding
- 48.72M
- Market Cap
- $1.88B
- Volume/Avg
- 423 / 816,516
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 13.21
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 291
- Website
- https://www.urogen.com
Valuation
|
Metric
|
URGN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 13.21 |
Price/Cash Flow | — |
Price/Earnings
URGN
Financial Strength
|
Metric
|
URGN
|
|---|---|
Quick Ratio | 3.86 |
Current Ratio | 4.69 |
Interest Coverage | −8.25 |
Quick Ratio
URGN
Profitability
|
Metric
|
URGN
|
|---|---|
Return on Assets (Normalized) | −52.31% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −239.33% |
Return on Assets
URGN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|yV<#>h | LOCK|bRW% | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>zXh<z^ | LOCK|QS?> | $70B | |||
| argenx SE ADR
ARGX
| LOCK|cF<Vjl | LOCK|G& | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%ldr<<< | LOCK|sRh^ | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|fdBLvT^ | LOCK|RWq | $36B | |||
| Moderna Inc
MRNA
| LOCK|Ts%lH$ | LOCK|WH! | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|V^$FTTxH | LOCK|B!$p | $25B | |||
| Incyte Corp
INCY
| LOCK|J?<Gq%% | LOCK|T$ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|kG&%$RP | LOCK|tw$ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|%^T&?r | LOCK|!V | $17B |
United States